Technical Analysis for INNT - Innovate Biopharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.22 -0.89% -0.02
INNT closed down 0.89 percent on Thursday, January 17, 2019, on 23 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical INNT trend table...

Date Alert Name Type % Chg
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 17 Stochastic Buy Signal Bullish 0.00%
Jan 17 Bollinger Band Squeeze Range Contraction 0.00%
Jan 17 Narrow Range Bar Range Contraction 0.00%
Jan 17 NR7 Range Contraction 0.00%
Jan 17 Inside Day Range Contraction 0.00%
Jan 17 Oversold Stochastic Weakness 0.00%
Jan 16 20 DMA Resistance Bearish -0.89%
Jan 16 Shooting Star Candlestick Bearish -0.89%
Jan 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.89%

Older signals for INNT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.
Is INNT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 50.5
52 Week Low 2.12
Average Volume 461,414
200-Day Moving Average 9.5072
50-Day Moving Average 2.6898
20-Day Moving Average 2.341
10-Day Moving Average 2.323
Average True Range 0.2409
ADX 14.13
+DI 23.4532
-DI 18.2061
Chandelier Exit (Long, 3 ATRs ) 2.1673
Chandelier Exit (Short, 3 ATRs ) 2.8427
Upper Bollinger Band 2.5571
Lower Bollinger Band 2.1249
Percent B (%b) 0.22
BandWidth 18.462196
MACD Line -0.1489
MACD Signal Line -0.166
MACD Histogram 0.0171
Fundamentals Value
Market Cap 20.75 Million
Num Shares 9.35 Million
EPS -0.89
Price-to-Earnings (P/E) Ratio -2.49
Price-to-Sales 1.94
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.31
Resistance 3 (R3) 2.31 2.29 2.30
Resistance 2 (R2) 2.29 2.26 2.29 2.29
Resistance 1 (R1) 2.25 2.25 2.24 2.25 2.28
Pivot Point 2.23 2.23 2.22 2.23 2.23
Support 1 (S1) 2.19 2.20 2.18 2.19 2.16
Support 2 (S2) 2.17 2.19 2.17 2.15
Support 3 (S3) 2.13 2.17 2.15
Support 4 (S4) 2.13